Vascular Targeted Photodynamic Tx Tied to Good Outcomes in Low-Risk PCa

This article originally appeared here.
Share this content:
Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.
Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.

(HealthDay News) — For men with low-risk prostate cancer, vascular targeted photodynamic therapy achieves an 82% rate of absent clinically significant cancer in treated lobes, according to a study published in the August issue of The Journal of Urology.

Souhil Lebdai, MD, from the University Hospital of Angers in France, and colleagues followed 82 men treated with vascular targeted photodynamic therapy for low-risk prostate cancer every 6 months. Six months after treatment or when there was biological or clinical progression, patients underwent prostate biopsies.

Patients were followed for a median of 68 months. The researchers found that median progression-free survival was 86 months. Six months after treatment, there was a significant 41% decrease in median prostate-specific antigen, which remained stable during follow-up (P <.001). One hundred fifteen lobes were treated and 82% achieved absent clinically significant cancer. Twenty of the patients (24%) underwent radical therapy, including 18 and 2 patients who underwent radical prostatectomy and brachytherapy, respectively, at a median of 22 months.

"Padeliporfin vascular targeted photodynamic therapy for low-risk prostate cancer achieved an 82% rate of absent clinically significant cancer in treated lobes and 76% of patients avoided radical therapy at a median follow-up of 68 months," the authors write. "However, longer term follow-up is required to determine long-term outcomes."

One author disclosed financial ties to Steba Biotech, which funded the study.

Reference

  1. Lebdai S, Bigot P, Leroux PA, et al. Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes. J Urol. 18 March 2017. doi: 10.1016/j.juro.2017.03.119
You must be a registered member of Renal and Urology News to post a comment.

Sign up for free e-Newsletters